NCT05188976

Brief Summary

The investigators aim to evaluate the correlation between PetCO2, PaCO2, and PtcCO2 in patients with respiratory diseases. The investigators also evaluate the correlation between PetCO2, PaCO2, and PtcCO2 changes over time.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Dec 2021

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2021

Completed
26 days until next milestone

First Submitted

Initial submission to the registry

December 27, 2021

Completed
16 days until next milestone

First Posted

Study publicly available on registry

January 12, 2022

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2024

Completed
Last Updated

March 28, 2023

Status Verified

March 1, 2023

Enrollment Period

3 years

First QC Date

December 27, 2021

Last Update Submit

March 25, 2023

Conditions

Respiratory Disease

Keywords

PetCO2

Outcome Measures

Primary Outcomes (1)

  • Correlation between PetCO2, PaCO2, and PtcCO2

    One to three months

Secondary Outcomes (2)

  • Correlation of changes over time between PetCO2, PaCO2 , and PtcCO2

    One to three months

  • Relationship between PetCO2 and respiratory symptoms evaluated by The COPD Assessment Test (CAT) and mMRC (modified British Medical Research Council)

    One to three months

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Subjects with respiratory disease such as COPD, IP

You may qualify if:

  • Subjects with respiratory disorder.
  • Subjects who are clinically stable for the last 2 weeks

You may not qualify if:

  • Subjects who required treatment with antibacterial agents or oral/intravenous steroids for pneumonia or exacerbation of respiratory disease in the last 2 weeks.
  • Subjects with severe complications such as cardiovascular disease, liver disease, renal disease, and neurological disease.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Hospital Organization Minami Kyoto Hospital

Jōyō, Kyoto, 610-0113, Japan

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Arterial blood gas

MeSH Terms

Conditions

Respiration Disorders

Condition Hierarchy (Ancestors)

Respiratory Tract Diseases

Central Study Contacts

Yuichi Chihara, MD., PhD.

CONTACT

81-774-52-0065yc.r03107@gmail.com

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 27, 2021

First Posted

January 12, 2022

Study Start

December 1, 2021

Primary Completion

December 1, 2024

Study Completion

December 1, 2024

Last Updated

March 28, 2023

Record last verified: 2023-03

Locations

JP(1)